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http://dx.doi.org/10.1016/j.ccr.2013.12.006SUMMARYThe heterogeneity of brain cancers, as most solid tumors, complicates diagnosis and treatment. Identifying
and targeting populations of cells driving tumorigenesis is a top priority for the cancer biology field. This is not
a trivial task; considerable variance exists in the driving mutations, identifying markers, and evolutionary
pressures influencing initiating cells in different individual tumors. Despite this, the ability to self-renew
and differentiate must be conserved to reseed a heterogeneous tumor mass. Focusing on one example of
a tumor-initiating cell population, we demonstrate that the atypical cyclin-like protein Spy1 plays a role in
balancing the division properties of glioma cells with stemness properties. This mechanistic insight may pro-
vide new opportunities for therapeutic intervention of brain cancer.INTRODUCTION
Primary brain tumors can be driven by a population of brain
tumor-derived cells with stem-like characteristics or brain
tumor-initiating cells (BTICs) (Hemmati et al., 2003; Singh et al.,
2004). Whether these cells arise through dedifferentiation of line-
age-specified progenitors or through malignant transformation
of endogenous neural stem cells (NSCs) is a subject of much
debate. Regardless of the origin, understanding how BTICs
regulate growth and development is of utmost importance for
future treatment strategies (Dean et al., 2005). One commonality
amongBTICs is that they possess stem cell properties and, anal-
ogous to the hematopoietic system, express markers character-
istic of primitive neural cells (Chen et al., 2010; Hemmati et al.,
2003). Understanding themechanisms regulating NSCdecisions
may reveal key mediators dictating the initiation and continued
growth of BTICs.
The development of the mammalian brain depends on sym-
metric division of theNSCpopulation to expand the pool of prolif-
erating stem cells, followed by a switch to asymmetric division to
generate the neurons and glial cells in the brain,whilemaintainingSignificance
Brain tumor-initiating cells represent a highly tumorigenic subp
chemotherapy makes this subpopulation a challenge in advan
sion of this specific group of cells requires a complete understa
in normal neural stem cells. Our data provide insight into how o
relies on a specific cell-cycle regulator to coordinate the fine b
64 Cancer Cell 25, 64–76, January 13, 2014 ª2014 Elsevier Inc.the NSC population (Go¨tz and Huttner, 2005). Cell-cycle regula-
tion appears to underlie the transition between expansion of pro-
genitor pools and differentiation decisions (Dehay and Kennedy,
2007). Lengthening the cell cycle in vitro by inhibiting the cyclin-
dependent kinases (CDKs) induces premature generation of
neurons (Calegari and Huttner, 2003). Alternately driving the cell
cycle by overexpressing CDKs or G1/S cyclins leads to the
expansion of neural progenitor cells in themouse brain (Artegiani
et al., 2012; Lange et al., 2009). Stimulating neuronal differentia-
tion in cell culture downregulates endogenous levels and activity
of theG1/SCDK,CDK2, aswell as increasing protein levels of the
CDK inhibitor p27Kip1 (p27) (Dobashi et al., 2000; Kranenburg
et al., 1995). CDK2 knockout mice have marked defects in the
proliferative capabilities and self-renewal of adult neural progen-
itors in the subventricular zone (SVZ) (Jablonska et al., 2007).
Indeed, enhanced CDK2 activity and downregulation of p27 are
observed in many cases of brain cancer (Fiano et al., 2003; Hem-
mati et al., 2003; Narita et al., 2002). CDK inhibitors have shown
efficacy in human glioma in vitro (Jane et al., 2006); however,
many biological questions remain to be elucidated before this
approach can be reliably used in vivo. Intriguingly, the BTICopulation within the tumormass. Resistance to radio- and/or
cing medicine. Resolving the mechanism driving the expan-
nding of cell division and differentiation processes occurring
ne population of neural cells with stem/progenitor properties
alance of fate decisions.
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lators and reduced levels of cell-cycle inhibitors (Hidaka et al.,
2009). Understanding the roles of the core cell-cycle machinery
in BTIC expansion has important implications in the treatment
of brain cancers.
CDK activity is regulated by the relative abundance of its
cyclin-binding partner. More recently, a highly conserved family
of ‘‘cyclin-like’’ proteins, called the Speedy/RINGO family, has
emerged that is regulated developmentally and in a tissue-spe-
cific manner (Cheng et al., 2005b). The originally characterized
member, Spy1A1 (herein referred to as Spy1), is found at
elevated levels in several cancers (Al Sorkhy et al., 2012; Goli-
pour et al., 2008; Porter et al., 2002; Zhang et al., 2012). Spy1
can directly bind and activate the CDKs independent of phos-
phorylation within the T-loop of the CDK and with decreased
dependency on dephosphorylation by the Cdc25 phospha-
tases (Cheng et al., 2005a). This manner of activating CDKs
implies a mechanism by which Spy1 can bypass classically
defined cell-cycle checkpoints. Indeed, Spy1 is required for
cell-cycle re-entry in maturing vertebrate oocytes (Arumugam
et al., 2012; Lenormand et al., 1999). The Spy1 gene, SPDYA,
was initially isolated as a gene that conferred resistance to
UV damage in a RAD1-deficient strain of Schizosaccharomyces
pombe (Lenormand et al., 1999). Since this time, Spy1 protein
has been shown to override a number of cell-cycle checkpoints
and is capable of directly binding and promoting degradation of
p27 (McAndrew et al., 2007; Porter et al., 2003).The implication
of this in the molecular processes regulating development and
aging is also interesting. In mammary progenitor cells, Spy1
levels are tightly regulated through normal development and
accumulated protein levels abrogate differentiation and pro-
mote precocious development (Golipour et al., 2008). In the
acute sciatic injury model, Spy1 levels are dramatically upregu-
lated in populations of proliferating astrocytes and microglia
of the lumbar spinal cord, consequently implicating Spy1
in the regenerative processes of this system (Huang et al.,
2009). Interestingly, upregulation of Spy1 is accompanied by
an increase in CDK2 activity and downregulation of p27 in
this system. Recently, Zhang et al. (2012) demonstrated that
Spy1 levels are elevated in malignant human glioma and the
protein levels correlate with poor prognosis. The objective of
this work was to determine the role of Spy1-directed CDK
activity in human glioma.
RESULTS
Spy1 Protein Levels Are Elevated in Multiple Types of
Glioma and Correlate with Increasing Tumor Grade
Analysis of the protein levels of Spy1 in oligoastrocytoma (OAC;
Figure 1A), oligodendroglioma (ODG; Figure 1B), and invasive
glioblastomamultiforme (GBM; stage IV astrocytoma; Figure 1C)
was conducted using tissues obtained from the Ontario Brain
Tumor Tissue Bank. Each sample set analyzed consisted of
tissue derived from the tumor center (I), peritumor (II-IV), and
normal tissue (V). Average levels of Spy1 protein from tumor
center out to normal tissue were calculated over three sets of
samples per patient (Figures S1A–S1C available online). Spy1
protein levels were significantly elevated in the tumor tissue
over normal in 3 of 4 OAC and ODG sample sets and 1 of 4GBM sample sets (Figure S1A–S1C). Notably, tumor samples
from patients 865 (OAC; Figure 1A), 976, and 977 (GBM; Fig-
ure 1C) were noted as being highly necrotic in patient records,
and Spy1 levels were not elevated in these samples. In all 32
sample sets, combined Spy1 protein levels were significantly
elevated in 63% of samples from the tumor center and 62%
of peritumor samples in comparison to the pair matched control
tissues.
To further correlate the levels of Spy1 protein with the grade
of brain tumor, we utilized tissue microarrays (TMAs) consisting
of 188 different patient cores, including cores taken from non-
cancerous (normal) brain samples. Representative hematoxylin
and eosin-stained core images are presented in Figure S1H.
Immunohistochemistry (IHC) performed on TMAs revealed
extensive Spy1 staining in tumor tissues over pair-matched adja-
cent normal brain tissues taken from the same patients (Fig-
ure 1D; Figure S1I). Spy1 protein levels were progressively
elevated with increasing grade of astrocytoma, demonstrating
statistical significance over benign tissue as well as both pair
match normal adjacent tissue and noncancerous normal tissues
(combined as ‘‘normal’’) (Figure 1E). Although sample numbers
were limited, we found that Spy1 levels correlated with
increasing grade of OAC (Figure S1D) and ODG (Figure S1E).
Overall, protein levels of Spy1 were elevated at least 2-fold in
69% of the glioma tumor samples (Figures 1A–1E; Figures S1D
and S1E). Work performed by The Cancer Genome Atlas
(TCGA) research network demonstrated a strong correlation be-
tween the established GBM classes and normal neural lineages
(Verhaak et al., 2010). Notably, we found that in comparison to
primary neural cells cultured in monolayer, Spy1 expression
levels are significantly upregulated in neurospheres derived
from clonal expansion of those cells and correlate with the
expression of stemness markers, such as Nestin and Vimentin
(Figure S1G).
Amplification of the SPDYA Locus Correlates with Poor
Patient Prognosis
To determine if alterations at the genetic locus of Spy1 could be
implicated in patient prognosis, survival data from the Rem-
brandt NCI database were used to evaluate the effects of Spy1
and the Spy1 effector CDK2 on overall patient survival (NCI,
2005). CDK2 was found to be overexpressed in 236 out of
343 cases of all glioma, and overexpression very significantly
correlated with reduced patient survival, p < 0.001 (Figure 1F).
Importantly, there were no cases of downregulation of CDK2 in
all 343 cases. Similarly, in the data set of Li et al. (2009a) consist-
ing of 257 patients, there were 198 cases with upregulated
CDK2, no cases of significant downregulation, and upregulation
very significantly correlated with decreased survival, p < 0.001
(data not shown). SPDYA was found to be amplified in 31 of 56
cases of ODG, and amplification statistically correlated with
reduced patient survival, p = 0.01 (Figure S1F). SPDYA was
amplified in 3 of 5 cases of mixed glioma, and amplification
correlated with reduced patient survival, p = 0.06 (data not
shown). For total glioma cases, SPDYA was amplified in 143
out of 222 cases of all glioma, and amplification significantly
correlated with reduced patient survival, p = 0.005 (Fig-
ure 1G). Notably, the Rembrandt database does not specify
whether locus amplification is due to events such as focalCancer Cell 25, 64–76, January 13, 2014 ª2014 Elsevier Inc. 65
Figure 1. Spy1 Protein Is Overexpressed in High-Grade Glioma
(A–C) Spy1 protein expression in human brain tumor tissues microdissected from OAC (A), ODG (B), and GBM (C) patients. Biopsies were taken from the tumor
center (I), peritumor (near tumor infiltrate-scant tumor cells [II–IV]), or normal brain tissue (V). Patient identifier number is noted in each panel. One representative
blot of three is depicted. Values presented as the mean of integrated density values (IDV) Spy1/Actin. Average values over three blots of the same sample set are
quantified in Figures S1A–S1C.
(legend continued on next page)
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Figure 2. Spy1 Levels Are Essential for
Proliferation and Stem-like Properties of
Human Glioma Cells
(A) Growth curves measured by trypan blue
exclusion for U87 (left), SJ-GBM2 (middle), and
U251 (right). See Figure S2A.
(B) Growth curves measured by trypan blue
exclusion for human primary brain tumor cells
(patient identifier numbers: 2303, 3054, 3077,
2587, and 3035) presented as a percentage of
proliferating cells relative to control at the indi-
cated time points. See Figure S2B.
(C) Imaging (left panel) and quantification (right
panel) of U87 cells positive for BrdU staining. Data
are shown asmean ± SD. At least five fields of view
per infection. Scale bar, 10 mm.
(D) qRT-PCR of U87 cells infected with scrambled
control (pLKO) or two different shRNA against
Spy1 (black bars) or CycE1 (hollow bars). Genes
indicated on x axis. See Figures S2C and S2D.
All data are shown as mean ± SD; *p < 0.05, **p <
0.01, ***p < 0.001. n = 3 for each panel. All p values
are based on analysis control versus treatment.
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Cell-Cycle Regulation of Glioma Stem-like Cellsamplification or whole arm gain. Nonetheless, from these data,
amplification of SPDYA and overexpression of the Spy1 effector,
CDK2, significantly correlate with reduced survival in glioma
patients.
Knockdown of Spy1 Reduces Proliferation and
Stemness Properties in Human Glioma
To address the importance of Spy1 in brain tumorigenesis
in vitro, we utilized the human U-87MG (U87), SJ-GBM2,(D andE) TMAscontainingnormal brain anddiverse brain tumor tissue samples stained for Spy1expression. Th
(TOTO-3) signal. See Figures S1H and S1I. (D) IHC of Spy1-positive cells in astrocytoma tissues of different g
brain tissue (white bars) over twoseparate arrays.Grade I–II astrocytoma (n=3), grade III astrocytoma (n=3), an
(E) Spy1 protein levels analyzed in different grades of astrocytoma (I–III) (n = 112), GBM (n = 24), benign brain
(F and G) Patient survival data fromRembrandt NCI database correlated with CDK2 expression levels over all g
from all glioma data (G). See Figure S1F.
All data are shown as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001.
Cancer Cell 25, 64–7and U251 glioma cell lines, as well as
primary cells obtained from six con-
senting patients. The heterogeneous
U87 and U251 lines are driven by a
well-characterized pool of highly tumor-
igenic cells that stain positive for the
cell-surface marker CD133 (CD133+)
(Jin et al., 2011; Kelly et al., 2010).
The SJ-GBM2 cells are established
from an aggressive pediatric glioma
and also possess a significant CD133+
population (Donovan et al., 2012; Mid-
dlemas et al., 2000). Cells were in-
fected with lentivirus carrying two
different small hairpin RNA (shRNA)
constructs against Spy1 (shSpy1) or a
scrambled control (pLKO) and were
subsequently selected. Both of the
Spy1-shRNA constructs effectivelyreduced their targeted genes at least 3-fold (Figure S2A).
Proliferation kinetics show that Spy1-knockdown (KD) signifi-
cantly reduces cell growth in all cell lines tested (Figure 2A)
and in 4 out of 5 primary lines (Figures 2B and S2B). In the -
primary tumor cells, the effect of Spy1-KD was rescued by
overexpression of a human Spy1 plasmid resistant to knock-
down with Spy1-shRNA (pEIZ-Rescue); this confirms target
specificity (Figure S2B). Results were confirmed by BrdU
incorporation in the U87 line, where the shSpy1 cells showedeSpy1signal intensity is normalized tonuclear stain
rade (black bars) in comparison to normal adjacent
d normal controls (n =6). SeeFiguresS1DandS1E.
tumors (n = 8), and normal controls (n = 19).
lioma samples (F) or SPDYA amplification/deletion
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Figure 3. Spy1 Expression Plays a Critical Role in the Stemness Properties of the CD133+ BTIC Population
(A) qRT-PCR of U87 cells cultured as monolayer (ML) or in a neurosphere formation assay (NS) at passage 5.
(B) U87 cells sorted and CD133+ and CD133 populations analyzed by qRT-PCR for CD133 (upper panel) and Spy1 (lower panel) levels.
(C) CD133+ and CD133 populations analyzed by qRT-PCR for several genes. The CD133+ population is compared to the CD133 population. p values are
presented.
(D) U87 cells sorted for CD133 (confirmed by qRT, top right graph). The CD133+ population was infected with either shRNA control (pLKO) or one of two shSpy1
constructs (shSpy1#1 [solid bars] or shSpy1#2 [hollow bars]). Knockdown confirmed by qRT-PCR (lower right graph). Effects on gene expression reported as
relative expression of shSpy1over pLKO control (lower left graph). p values are presented.
(legend continued on next page)
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cells (Figure 2C).
Marker analysis in three different human primary cell lines
determined that collectively Spy1-KD caused significant down-
regulation of CD133, downregulation of Nestin, and significant
upregulation of b-III Tubulin levels (Figure S2C). Spy1-KD in
U87 cells significantly reduced expression of the proliferation
marker Ki67 and enhanced expression of p27 (Figure 2D).
Interestingly, Spy1-KD also correlated with increased levels of
the growth-associated protein 43 (GAP43), a marker of mature
neurons, and decreased levels of markers known to identify
normal stem-like cells and BTICs, CD133, and glial fibrillary
acidic protein (GFAP). These data prompted the hypothesis
that Spy1 levels may be important for both proliferation and
directing the fate of at least subsets of cells within the hetero-
geneous tumor.
Spy1 binds and activates CDK2 in a manner distinct from that
of classical cyclin proteins, and Spy1-bound CDK2 has altered
substrate specificity when compared to Cyclin E/A-bound
CDK2 (Cheng et al., 2005a). Hence, to determine if Spy1 has
unique roles in proliferation and stemness in human glioma, we
compared Spy1-KD effects to reduced expression of Cyclin
E1 (CycE1) in a heterogeneous population of U87 cells. Here,
we targeted CycE1 using two different shRNA constructs (Fig-
ure S2D).We found that therewere some similarities in response,
where both Spy1-KD and CycE1-KD reduced expression of the
stemnessmarkers GFAP and CD133 (Figure 2D). However, there
were also some pronounced differences; CycE1-KDdid not have
a significant effect on the proliferation marker Ki67 and had an
opposite effect on both p27 and the neuronal differentiation
marker GAP43.
Spy1 Regulates Stemness Properties of the CD133+
Glioma Population
To determine the potential role of Spy1 in the BTIC populations
with neurosphere formation capacity, U87 cells were cultured
and passaged in monolayer or as spheres to promote self-
renewal in vitro (Lee et al., 2006). Spy1 expression levels were
upregulated when cells were cultured as spheres (Figure 3A).
This increase correlated with upregulation of the stemness
markers Nestin and CD133 and downregulation of p27 and the
oligodendrocyte marker NG2 (Figure 3A). CD133-negative
(CD133) cells are capable of initiating tumors in vivo; however,
sorting for a CD133+ population in human glioma has been
shown to enrich sphere formation, initiate glioma in a mouse
xenograft model, and to correlate with decreased prognosis
for glioma patients (Bao et al., 2006; Zeppernick et al., 2008).
Spy1 expression is significantly higher in the CD133+ population,
and this correlates positively with expression of the stem/pro-
genitor markers Nestin and Vimentin (Figures 3B and 3C). This
population also expressed higher amounts of the prolifera-
tion marker Ki67 along with the oncogenes c-Myc and MycN
and reduced expression of p27 (Figure 3C). Additionally, the
CD133+ population was characterized by lower expression of(E) qRT-PCR for CD133+ cells infected with shSpy1, shCycE1, or scrambled sh-
(F) qRT-PCR of different markers (x axis) from the CD133+ population treated in pa
values are averaged over two separate shRNA constructs each ran in triplicate o
All data are shown as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001. Unless indoligodendrocyte markers Olig2 and NG2, which, along with the
upregulated levels of GFAP, suggests an astrocyte progenitor
lineage and supports NSC nature of these cells. Downregulation
of Bmi1 suggested that the sorted population represents
a higher stem-like hierarchy, as Bmi1 was recently shown to
mark progenitor populations at the intermediate stages of differ-
entiation within human glioma (Venugopal et al., 2012).
We then measured the effects of depleting Spy1 on stemness
characteristics of the CD133+ population in multiple established
cell lines. In U87 cells sorted for CD133 (Figure 3D, top panel),
Spy1-KD resulted in a marked reduction of CD133 levels that
occurred along with a decline in BTIC/proliferation markers
GFAP, Ki67, c-Myc, and upregulation of p27 levels (Figure 3D,
bottom left panel). These results were similar in other glioma
cell lines known to contain a CD133+ population (Figures S3A
and S3B). Notably, the c-Myc, Ki67, and p27 effects were not as-
sessed for significance in the U251 cells (Figure S3B). Although
both shRNA constructs consistently reduced CycE1 expression
at least 14-fold in the sorted population (Figure S3C) and signif-
icantly reduced kinase activity as compared to Spy1-KD (Fig-
ure S3D), there were no significant effects on the expression of
the BTIC marker CD133 (Figure 3E). Furthermore, only Spy1-
KD demonstrated a significant effect on reducing the stemness
markers Nestin andGFAP and increasing expression of neuronal
markers, such as GAP43, in the CD133+ population (Figure 3F).
Interestingly, KD of both Spy1 and CycE1 resulted in an increase
in Bmi1. It has recently been demonstrated that, whereas Bmi1
drives NSC self-renewal, expression tends to mark a population
of cells that is more differentiated than the CD133+ (Venugopal
et al., 2012). Collectively, these results support the conclusion
that inhibition of CDK2 activity begins to transition the CD133+
population to a more differentiated state, but CycE1-KD alone
is not sufficient to denote changes in stemness or more differ-
entiated markers.
Downregulation of Spy1 Is Critical for Specific
Differentiation Decisions
Given that Spy1-KD reduced expression of stem/progenitor
markers and increased neuronal differentiation markers, we
questioned whether Spy1 was endogenously regulated during
differentiation. The SVZ region of postnatal mouse brains were
microdissected at days 1–4 and grown as monolayer (Figure 4A)
or neurospheres (Figure S4A), followed by treatment with differ-
entiation stimuli. In both cases, Spy1 expression decreased
with differentiation morphology and correlated with a decrease
in stemness markers GFAP and Nestin and an increase in the
neuronal differentiation marker GAP43 (Figures 4A and S4A).
To determine whether decreasing levels of Spy1 protein are
essential for differentiation to occur, Spy1 or an empty vector
control were overexpressed in primary neural cells (Figure 4B).
We found that 60%of control spheres successfully differentiated
by 72 hr, whereas only 20% of Spy1-overexpressing neuro-
spheres were visibly differentiating (Figure 4B). Spy1-overex-
pressing cells, induced to differentiate, had reduced expressionControl (pLKO). Representative data are shown.
rt (E) above. Left panel reflects Spy1-KD, and the right panel reflects CycE1-KD;
ver three individual experiments.
icated, n = 3. See also Figure S3.
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Figure 4. Spy1 Overexpression Abrogates Neuronal Differentiation and Promotes Neurosphere Clonal Growth
(A) Differentiation of mouse primary neural cells recorded by phase contrast microscopy (upper panels; scale bar, 10 mm). qRT-PCR of Spy1, GAP43, and Nestin
tested along the differentiation time course (lower panel). Nontreated cells were used as a control.
(B) Primary neurospheres infected with pEIZ-SPDYA versus empty vector control (pEIZ) over the indicated time points. Morphology was monitored by light
microscopy (upper left panel). Scale bar, 25 mm. Differentiation was scored by neurite length and presented as the ratio of differentiated spheres to total spheres
(legend continued on next page)
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expression of the progenitor marker GFAP (Figure 4B). Although
levels of Nestin were increased, they were not significant (Fig-
ure 4B). Effects on mature astrocytes require further investiga-
tion pending the expansion of available markers. Depletion
of Spy1 in primary neural cells using shRNA demonstrated a
significant increase in functional differentiation; these effects
were rescued using the Spy1 rescue (pEIZ-Rescue) construct
(Figure S4C). These results support that elevated levels of
Spy1 favor expansion of stem/progenitor cells possessing glial
characteristics and prevent functional differentiation toward a
neuronal lineage.
To further determine whether Spy1 levels are critical for
normal stem/progenitor characteristics, primary neural cells
manipulated for Spy1 or control were assessed using estab-
lished assays to measure self-renewal capacity and neuro-
sphere formation (Guryanova et al., 2011; Lathia et al., 2010).
Spy1-overexpressing cells significantly increased the overall
number, clonality, and viability of neurospheres as compared
to controls (Figures 4C–4E). An opposite effect was observed
with Spy1-KD (Figure S4B). Cells overexpressing Spy1 had
notable elevation in the expression of stemness markers, such
as Nestin, Vimentin, and CD133 (Figure 4F). These data demon-
strate that the cyclin-like protein Spy1 is an important regulator in
the expansion and growth of NSCs. Although these data do not
reveal a cell of origin, we provide an additional mechanistic link
regulating the common growth characteristics between neural
stem/progenitor cells and BTIC populations.
Symmetric Division of CD133+ U87 Glioma Cells Relies
on Spy1
To assess the effects of Spy1 on the self-renewal characteristics
of BTICs in human glioma, cell lines, or primary brain tumor cells
with manipulated levels, either Spy1 or CycE1 were cultured at
low densities (<10 cells/well) in media supporting self-renewal.
Sphere formation was measured over 28 days after plating,
and spheres of 25 mm or more in diameter were scored (Figures
5A–5C). In the established cell lines, as well as in 3 out of 5
primary lines tested, Spy1-KD caused significant reduction in
both the number (Figures 5A–5C) and diameter (Figures 5B
and 5C) of resulting spheres; these are characteristics previously
correlated with tumorigenic capacity and percent of CD133+/
Nestin+ cells in glioma (Wang et al., 2008; Yoon et al., 2012).
In primary cells, the effect was significantly rescued, utilizing
the Spy1 pEIZ-Rescue construct altered to confer resistance
to shRNA used (Figure 5A). Sphere formation over an excess
of ten passages in CD133+ U87 cells revealed that Spy1-KD
caused a 5-fold decrease in number and longevity of spheres
compared to control (Figures S5A, left panel, and S5B). The
reciprocal effect was also noted in cells overexpressing Spy1(lower left panel). Control (hollow), Spy1 overexpressing (black bars). qRT-PCR of
(right panel top to bottom).
(C) Clonal assay performed on primary neural cells overexpressing Spy1 (pEIZ-S
(D) Neurospheres scored according to diameter after they were maintained in cu
(E) Longevity of pEIZ or pEIZ-SPDYA primary, secondary, and tertiary neurosphe
single cells every 6–9 days. Absorbance at 590 nm corrected for background ab
(F) qRT-PCR of stemness markers in pEIZ or pEIZ-SPDYA primary cells cultured
Unless indicated, data are shown as mean ± SD, n = 3. *p < 0.05, **p < 0.01, ***(pEIZ-SPDYA; Figure S5A, right panel). EGF and FGF are essen-
tial growth factors that support stem cell self-renewal (Li et al.,
2009b; Reynolds and Weiss, 1992). Interestingly, Spy1 overex-
pression resulted in a significant increase in CD133+ cells in
the absence of EGF/FGF (Figure S5C). This supports the hypoth-
esis that cell-cycle regulation by Spy1 may lie downstream of
associated growth factor signaling.
How BTICs use symmetric versus asymmetric division to
regulate expansion and support tumor growth is a very impor-
tant point not fully understood. Utilizing computer modeling,
Boman et al. (2007) have established that increasing symmetric
division is the only mechanism to adequately explain the
expansion of the cancer stem cell population. Drosophila and
mammalian systems have shown that symmetry of division is
influenced by the segregation of the protein Numb (Knoblich
et al., 1995; Lu et al., 1998). Numb is able to promote neural
differentiation, at least in part, through antagonizing Notch
and Hedgehog pathways; thus, localization of Numb serves as
an indicator of cellular fate determination (Couturier et al.,
2012; Di Marcotullio et al., 2006). Although the functional role
is unknown, we do know that asymmetric distribution of
CD133 also colocalizes with Numb in differentiating glioma
stem cells (Lathia et al., 2011). Utilizing the cell pair assay to
monitor protein expression in single cells through division, we
found that Spy1-KD resulted in marked asymmetric distribution
of both Numb (Figure 5D; Figures S5D and S5E) and CD133
protein (Figure 5D). Analysis over multiple infections of multiple
glioma cell lines with two separate knockdown constructs for
CycE1 and Spy1 showed significant asymmetric localization
of Numb protein in the Spy1-KD cells, but not in the CycE1-
KD cells (Figure 5D). The mode of division analysis utilizing hu-
man primary brain tumor cells revealed the same result, that the
depletion of Spy1, but not of CycE1, levels resulted in a signif-
icant increase in the number of cells dividing asymmetrically as
determined by Numb distribution (Figure 5E). Spy1-KD effects
were significantly reversed by the Spy1 pEIZ-Rescue construct.
Interestingly, Spy1-KD effects were also reversed by the over-
expression of CycE1, and effects were mimicked by the CDK2
inhibitor, NU2058. These data support the conclusion that
activation of CDK2 toward noncanonical substrates that are
preferred by Spy1-directed CDK activity (Cheng et al., 2005a),
but can also be activated by gross CDK activation, regulates
symmetric division in glioma stem cells. Western blot analysis
of Numb protein expression levels in CD133+ cells upon
Spy1-KD or CycE1-KD show that Spy1 downregulation, but
not downregulation of CycE1, causes a significant and repeat-
able accumulation of Numb protein levels (Figure 5F). Interest-
ingly, even within heterogeneous populations of human glioma,
Spy1 levels were found to inversely correlate with Numb and
p21 levels (Figure S5F). Collectively, these data support themarkers in control (pEIZ) and Spy1-overexpressing (pEIZ-SPDYA) primary cells
PDYA) versus control (pEIZ). Total neurosphere numbers indicated.
lture for 14–20 days. n = 2.
res (NS) in culture assessed by MTT assay. Neurospheres were passaged as
sorbance.
as neurospheres (NS).
p < 0.001. See also Figure S4.
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Figure 5. Spy1 Is Critical for Symmetric Division and Self-Renewal of CD133+ Cells
(A) Clonal assay performed on control (pLKO+pEIZ), shSpy1 (shSpy1+pEIZ), and overexpressing rescue vector (shSpy1+pEIZ-Rescue) human primary brain
tumor cells. Emerging neurospheres of over 25 mm scored per well. There is a minimum of 30 wells per replicate.
(B and C) As described for (A) using the CD133+-enriched U87 (B) and SJ-GBM2 (C) cells treated with pLKO-Control (pLKO), shSpy1#1/#2, and shCycE1#1/#2.
Neurosphere size is presented as a pie chart. Results obtained from both shRNA constructs were pooled for (C). See Figures S5A–S5C.
(D) Cell pair assay conducted using the CD133+ population of U87, SJ-GBM2, and U251 cells treated with pLKO-Control (pLKO), shSpy1#1/#2, and shCycE1#1/#2.
Representative U87 cells stained for Numb (left upper panel) and CD133 (left lower panel). Quantification of each cell type scored for Numb distribution (right
panel). Scale bars, 10 mm. See Figures S5D and S5E.
(E) Cell pair assay conducted using human primary brain tumor cells treated as above, as well as with shCycE1 (shCycE1+pEIZ), CycE1-overexpressing vector
alone (pLX-CycE1), or together with shSpy1 (shSpy1+pLX-CycE1), CDK2 inhibitor (pLKO+pEIZ+NU2058), and Spy1 rescue vector alone (pLKO-pEIZ-Rescue).
Quantification of each cell type was scored for Numb distribution (top panel). Representative cells were stained for Numb (red) and nuclei (blue) (bottom panel).
Scale bar, 10 mm.
(F) Levels of Numb protein in U87 cells treated with shSpy1 or shCycE1. One representative blot of three (upper panel).Values are presented as the mean of
integrated density values (IDV) Numb/Actin. See Figure S5F.
Unless indicated, data are shown as mean ± SD, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001.
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protein Spy1 promote NSC self-renewal and expansion of
stem/progenitor populations by regulating the balance of
symmetric versus asymmetric division.
DISCUSSION
The dynamics of neurogenesis relies on the balance of stem/
progenitor self-renewal with commitment to specific lineages.
Extensive literature indicates that antiproliferative genes pre-
venting the activation of G1/S CDKs act as important timers to
permit neurogenesis (Durand et al., 1998; Hindley and Philpott,
2012). Similarly, although not as extensively investigated, prolif-
erative genes and signals resulting in an activation of the G1/S
CDKs support expansion of stem/proliferative populations and
retard successful neurogenesis (Dobashi et al., 1995; Lange
and Calegari, 2010). Which cyclin-CDKs regulate specific neuro-
genic events and how their activation is controlled remain to be
elucidated. As multicellular organisms have evolved to possess
regenerative systems capable of sustaining long life, so have
the families of proteins regulating cell-cycle progression. The
Speedy/RINGO family of cyclin-like proteins is such an example.
Expressed in all vertebrates and some invertebrates, at least one
family member, Spy1, has demonstrated roles in spinal cord
regeneration and to possess stem-like qualities in the developing
mammary gland (Golipour et al., 2008; Huang et al., 2009). In this
work, we demonstrate that Spy1 is expressed at high levels in
clonally derived neurospheres and that levels decline during dif-
ferentiation. Elevated levels of Spy1 prevent functional differen-
tiation and enhance the number and longevity of neural stem/
progenitor cells able to grow in neurosphere culture. Although
the link between NSCs and BTICs remains to be determined,
BTICs are found to express several normal NSC markers and
possess growth characteristics mimicking that of normal NSCs
(Chen et al., 2012). Hence, regardless of the BTIC origin,
resolving the regulatory properties driving normal stem/progen-
itor cells may shed light on potential ways to target these aggres-
sive populations therapeutically.
A defining property of both NSCs and BTICs is the ability to
divide both symmetrically and asymmetrically. A shift in division
characteristics to favor symmetric division contributes to expo-
nential increase in the numbers of cancer stem cells in different
types of tumors (Go¨nczy, 2008). The critical switch between
modes of division correlates with changes in the cellular distri-
bution of the protein Numb (Song and Lu, 2012). Functionally,
Numb inhibits the Notch pathway to permit asymmetric division
and subsequent differentiation (Song and Lu, 2012). Our study
demonstrates that Spy1 is important for maintaining symmetric
mode of division and self-renewal, implicating a mechanistic
role for this ‘‘cyclin-like’’ protein in retaining the hallmark
properties of BTICs. Arumugam et al. (2012) pointed at the
Spy1 (referred to as RINGO in this publication)-CDK signaling
pathway as a highly conserved activator of Musashi-1 (Msi1)
during cell-cycle re-entry in oocyte maturation. Activated
mammalian Msi1 stimulates Notch signaling through the
translational repression of Numb (Imai et al., 2001). Hence,
Msi1 may rely on Spy1-directed CDKs to mediate self-renewal
of normal NSCs, as well as clonal expansion, malignancy, and
proliferation of glioblastoma cells (Muto et al., 2012; Sakakibaraet al., 2002). Our data reveal that Spy1-KD, but not CycE1-KD,
leads to increased levels of Numb, followed by altered expres-
sion of select Notch transcriptional targets. The altered regula-
tion of Numb, and consequently Notch, may also alter overall
self-renewal parameters. Noseda et al. (2004) showed that
Notch can act as a transcriptional repressor of p21, which
further prevents nuclear localization of Cyclin D-CDK4. In
mammals, p21 maintains quiescence of adult NSC populations
(Kippin et al., 2005). Hence, Spy1 appears to coordinate signals
directing both self-renewal and the balance of symmetric/
asymmetric division.
It is known that Spy1 activates CDKs in a Cyclin-Activating
Kinase (CAK)-independent manner and demonstrates less
stringent substrate specificity than cyclin-bound CDKs (Cheng
et al., 2005a). In addition, atypical of cyclins, Spy1 can both
activate CDKs and directly bind and promote the degradation
of the CDK inhibitor p27 (Porter et al., 2003). Functional differen-
tiation requires a decrease in the kinase activity of CDK2 as
well as an accumulation in p27 protein levels (Dobashi et al.,
1995; Sasaki et al., 2000). This work supports the specific
requirement for this class of proteins over the established
CDK2 partners during neural differentiation and in promoting
stemness properties in neural cells. The importance of these
‘‘cyclin-like’’ proteins has been overlooked in the cancer thera-
peutics arena for over a decade (Porter et al., 2002). Although
CDK inhibitors are being tested clinically for a number of
different types of cancer, the studies in brain malignancies
remain preliminary (Fischer and Lane, 2000; Jane et al., 2006).
In other types of cancer, despite the preclinical success of
this approach, the data on actual therapeutic outcome have
been quite disappointing (Stone et al., 2012). Our study adds
to the accumulating evidence that will aid in improving the effec-
tiveness of CDK inhibitors in their use as chemotherapeutic
agents for specific subsets of cancer.
Determining how to direct treatment to the appropriate patient
population is a pressing area of cancer research. Spy1 levels
were most significantly elevated in higher grades of glioma,
known to be more anaplastic with features resembling immature
astrocytes and/or oligodendrocytes. This correlates with the
elevated levels of glial progenitor markers seen in our cell sys-
tems overexpressing Spy1, such as the BTIC marker CD133. A
significant amount of data supports the use of CD133 as a
stem cell surface antigen to identify a subpopulation of brain
tumor-initiating stem cells (Singh et al., 2004). Whereas
CD133 BTIC populations are able to generate heterogeneous
tumors in vivo (Korur et al., 2009), tumors containing a CD133+
BTIC population correlate positively with higher grades of gli-
oma, poorer patient prognosis, and multidrug resistance (Dean
et al., 2005; Yan et al., 2011; Zeppernick et al., 2008). Resolving
the lineage commitment, stage of differentiation, and genetic/
genomic signatures of BTIC populations for the different forms
and stages of glioma is an essential next step in correlating prog-
nostic markers with effective treatments for brain cancers.
Importantly, Spy1-KD in a heterogeneous population of GBM
cells decreased the proliferative index, as well as the expression
levels of CD133 and GFAP. Abrogation of normal differentiation
events can contribute to the initiation of tumorigenesis, and
understanding such events has proven to constitute a valuable
strategy in the treatment of acute promyelocytic leukemiaCancer Cell 25, 64–76, January 13, 2014 ª2014 Elsevier Inc. 73
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valuable approach for a cancer of neural origin.
EXPERIMENTAL PROCEDURES
Animals
Balb/c mice (Jackson Laboratory) were maintained and cared for following the
regulatory standards identified by the Canadian Council for Animal Care.
Approval was provided by the University of Windsor animal care committee
(AUPP# 10-08).
Primary Mouse Cell Harvest and Culture
Tissues were microdissected, and primary cells were dissociated from the
region surrounding the SVZ of P1-P4 mouse brains as described previously
(Pacey et al., 2006). Cells were seeded at less than 5 3 104 cells per well in
six-well Ultra-Low Cluster Plates (ULCP) (Corning, 3471) and cultured in
serum-free Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s Nutrient
Mixture F-12 media (Sigma) containing N2 supplement hEGF (20 ng/ml;
GIBCO) and bFGF (10 ng/ml; Sigma), 2 mM L-glutamine at 37C in 5% CO2.
Formed spheres were subcultured every 5–10 days. Differentiation was con-
ducted on primary spheres in media supplemented with 2% FBS as described
previously (Kerosuo et al., 2008). Primary, secondary, and tertiary neuro-
spheres were dissociated, and 10,000 cells were seeded in 100 ml of media
in 96-well antiadhesive plates. MTT solution (20 ml of 5 mg/ml in PBS) was
added to each well and incubated for 4 hr. Extraction buffer (100 ml) was added
for 2 hr to dissolve the formazan crystals, and the absorbance at 590 nm was
assessed using Victor plate reader (PerkinElmer). Clonal assayswere conduct-
ed in neurosphere media in 96-well ULCP plates; cells were plated by serial
dilution; and wells containing 1–10 cells/well were included in experiments
and analysis.
Cell Lines
Human GBM U-87 MG cells were obtained from the American Type Culture
Collection. The U251 cell line was a kind gift from Dr. James Rutka (The Hos-
pital for Sick Children Research Institute, University of Toronto). The SJ-GBM2
cell line was obtained from The Children’s Oncology Group repository. U-87
MG and U251 cells were cultured in Eagle’s minimum essential medium
(EMEM; Sigma) and DMEM, respectively, supplemented with 10% FBS and
1% penicillin/streptomycin. SJGBM2 cells were cultured in Iscove’s modified
Dulbecco’s medium supplemented with 20% of FBS, 5 mg Insulin, 5 mg Trans-
ferrin, and 5 ng Sodium Selenite. All cells were maintained at 37C in 5% CO2.
Cell proliferation and viability were measured using trypan blue exclusion
assay. Cell numbers were quantified using a TC100 Automated Cell Counter
(BioRad).
Human Primary Cell Harvest and Culture
Resected tumors were collected at the Henry Ford Hospital, with written
consent from patients in accordance with institutional guidelines as approved
by the Institutional Review Board at Henry Ford Hospital. Pathology was
graded according to the WHO criteria. The cells were extracted and cultured
as spheres as described previously (deCarvalho et al., 2010).
Cell Sorting
Cells were incubated for 48 hr in stem cell media. Pellets were resuspended in
PBS buffer (pH 7.4) containing 0.1% BSA, (B1). Magnetic beads (Dynabeads
M-450 Epoxy, Invitrogen) labeled with CD133 antibody were incubated with
2.5 3 106 cells in 1 ml B1 solution. Suspension was incubated 20 min at 4C
with gentle rotation followed by 2 min positive isolation using EasySep magnet
(Stem Cell Technologies, #18000). Bead-bound cells were washed 4 times
using 1 ml PSB buffer.
Cell Pair Assay and Immunofluorescence
Single cells were isolated with 0.05% Trypsin-EDTA and plated in a drop of
media onto MaxGel ECM-coated (Sigma, E0282) coverslips. Cell division
was monitored over 20 hr and then fixed in 3.7% paraformaldehyde (PFA)
for 20 min at room temperature. Cells were washed, permeabilized, and incu-
bated with 1:200 Numb antibody (Cell Signaling, C29G11). Alexa-488 conju-74 Cancer Cell 25, 64–76, January 13, 2014 ª2014 Elsevier Inc.gated secondary antibody (1:1,000 dilution) (Invitrogen) was applied for
1/2 hr. Nuclei were stained with TOTO-3 T-3600 (Molecular Probes). CD133
antibody (Abcam, 27699) staining was performed directly in media without fix-
ation and was followed by the immunofluorescence protocol. Five random
fields of view were scored for Numb protein distribution in mitotic cell pairs/
treatment/replicate. Primary brain tumor cells were incubated with CDK2 in-
hibitor NU2058 at the concentration of 30 mM in media for 48 hr. Analysis
was performed using Leica CTR 6500 microscope (Leica Microsystems) and
AF software.
Statistical Analysis
Student’s t test was used, and a p value of 0.05 was considered significant. All
data are reported as means ± SD. qRT-PCR statistics were performed as
described previously (Yuan et al., 2006). Briefly, the Ct value of the house-
keeping gene (GAPDH) was subtracted from the corresponding Ct value of
a target gene, producing the dCt value that was further subjected to the
Student’s t test analysis. Statistical analyses and normality testing were
performed using Statistica software.
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